Drug Discovery Today
DECEMBER 3, 2021
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech companies has announced a breakthrough in laboratory trials of a new drug to treat COVID-19 and new variants of the disease, such as the Omicron variant.
Drug Patent Watch
NOVEMBER 30, 2021
This chart shows the drugs with the most patents in Denmark. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Denmark? appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
NOVEMBER 30, 2021
ICYMI, CVS Health recently announced that it will close about 900 of its retail pharmacies. This downsizing complements the company’s shift toward its healthcare delivery future. This long-overdue move highlights the retail industry’s fundamental economic headwinds. The pharmacy shakeout is accelerating, as smaller competitors exit and larger companies reduce store count.
The Pharma Data
DECEMBER 3, 2021
In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two treatment courses in total. Zuranolone 50 mg was generally well-tolerated with an overall adverse event profile consistent with data reported earlier and 6.5% of patients discontinuing study drug due to adverse events.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
PerkinElmer
DECEMBER 3, 2021
G-protein coupled receptors (GPCRs) are the largest and most diverse family of membrane receptors in the human genome and are targeted by around one third of drugs currently approved by the FDA. These proteins represent one of the most extensively studied targets for drug discovery, mainly due to their involvement in a plethora of signaling pathways and pathophysiological processes in the human body.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Channels
DECEMBER 2, 2021
Looking for a thoughtful and timely stocking stuffer? I suggest Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic , by Scott Gottlieb, M.D. (Amazon link). This book provides a comprehensive, well-written chronicle of the COVID-19 pandemic (as of mid-2021). Dr. Gottlieb documents—with great specificity—how and why our government’s public health infrastructure failed us during the pandemic.
The Pharma Data
NOVEMBER 29, 2021
Since the emergence of the COVID-19 epidemic, Johnson & Johnson (the Company) has been nearly covering recently arising COVID-19 variants. In collaboration with academic groups in South Africa and around the world, the Company has been assessing the effectiveness of its COVID-19 vaccine across variants, including now the new and fleetly spreading Omicron variant.
Practical Cheminformatics
NOVEMBER 30, 2021
Here's a quick post based on a conversation with a friend who wanted to be able to cluster a set of docked molecules based on fingerprints and select the highest scoring molecule(s) from each cluster. As usual, Pandas made this super easy. The code for this example can be run on Colab and is also available as a Gist.
Drug Patent Watch
NOVEMBER 30, 2021
Annual Drug Patent Expirations for FLOVENT+HFA Flovent Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from four suppliers. There are…. The post New patent expiration for Glaxo Grp drug FLOVENT HFA appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
DECEMBER 2, 2021
Annual Drug Patent Expirations for OXTELLAR+XR Oxtellar Xr is a drug marketed by Supernus Pharms and is included in one NDA. It is available from one supplier. There are nine…. The post New patent for Supernus Pharms drug OXTELLAR XR appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 2, 2021
This chart shows the pharmaceutical companies with the most patents in Denmark. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Denmark? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 2, 2021
Annual Drug Patent Expirations for SKELAXIN Skelaxin is a drug marketed by King Pharms and is included in one NDA. It is available from four suppliers. There are two patents…. The post New patent expiration for King Pharms drug SKELAXIN appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 2, 2021
Annual Drug Patent Expirations for TYVASO Tyvaso is a drug marketed by United Therap and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for United Therap drug TYVASO appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
DECEMBER 2, 2021
Annual Drug Patent Expirations for KUVAN Kuvan is a drug marketed by Biomarin Pharm and is included in two NDAs. It is available from two suppliers. There are eleven patents…. The post New patent for Biomarin Pharm drug KUVAN appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 2, 2021
Annual Drug Patent Expirations for EXPAREL Exparel is a drug marketed by Pacira Pharms Inc and is included in one NDA. It is available from one supplier. There are two…. The post New patent for Pacira Pharms drug EXPAREL appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 2, 2021
Annual Drug Patent Expirations for TRUSELTIQ Truseltiq is a drug marketed by Helsinn Hlthcare and is included in one NDA. There are three patents protecting this drug. This drug has…. The post New patent for Helsinn Hlthcare drug TRUSELTIQ appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 2, 2021
Annual Drug Patent Expirations for BALCOLTRA Balcoltra is a drug marketed by Avion Pharms and is included in one NDA. It is available from one supplier. There is one patent…. The post New patent for Avion Pharms drug BALCOLTRA appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
DECEMBER 2, 2021
Annual Drug Patent Expirations for DETECTNET Detectnet is a drug marketed by Radiomedix and is included in one NDA. It is available from one supplier. There are two patents protecting…. The post New patent for Radiomedix drug DETECTNET appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 1, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Finland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
DECEMBER 1, 2021
Annual Drug Patent Expirations for REQUIP+XL Requip Xl is a drug marketed by Glaxosmithkline Llc and is included in one NDA. There are two patents protecting this drug and seven…. The post New patent expiration for Glaxosmithkline Llc drug REQUIP XL appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
NOVEMBER 29, 2021
The U.S. Food and Drug Administration today approved Cytalux (pafolacianine), an imaging drug intended to assist surgeons in identifying ovarian cancer lesions. The drug is designed to improve the ability to locate additional ovarian cancerous tissue that is normally difficult to detect during surgery. Cytalux is indicated for use in adult patients with ovarian cancer to help identify cancerous lesions during surgery.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
The Pharma Data
NOVEMBER 29, 2021
Amgen Ranks in Top 10% of Biotechnology Companies Worldwide, Earning Top Scores in Business Ethics, Philanthropy, and Environmental Reporting. Amgen today announced that it has been named to the Dow Jones Sustainability World Index for the eighth consecutive year, reflecting the company’s enduring commitment to environmental, social, and governance (ESG) issues.
The Pharma Data
NOVEMBER 29, 2021
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla ® (apremilast) and placebo in treating adults with moderate to severe plaque psoriasis. U.S. Food and Drug Administration assigned a target action date of September 10, 2022; European Medicines Agency validation confirms the submission is complete and begins the centralized review process.
The Pharma Data
NOVEMBER 29, 2021
First Combination of Immunotherapy With Tyrosine Kinase Inhibitor Approved in Europe for Adult Patients With Advanced or Recurrent Endometrial Carcinoma With Disease Progression on or Following Prior Treatment With a Platinum-Containing Therapy in Any Setting and Who Are Not Candidates for Curative Surgery or Radiation. Approval Based on KEYNOTE-775/Study 309 Results Demonstrating Statistically Significant Improvements in Overall Survival and Progression-Free Survival Compared With Chemotherapy.
The Pharma Data
NOVEMBER 29, 2021
On 26 November 2021, WHO designated the variant B.1.1.529 a variant of concern, named Omicron, on the advice of WHO’s Technical Advisory Group on Virus Evolution (TAG-VE). This decision was based on the evidence presented to the TAG-VE that Omicron has several mutations that may have an impact on how it behaves, for example, on how easily it spreads or the severity of illness it causes.
Drug Patent Watch
NOVEMBER 29, 2021
Annual Drug Patent Expirations for XARELTO Xarelto is a drug marketed by Janssen Pharms and is included in one NDA. It is available from three suppliers. There are four patents…. The post New patent for Janssen Pharms drug XARELTO appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
113 
Let's personalize your content